MK-1775

首页 / 抑制剂/激动剂 / 细胞周期 / Wee1 / MK-1775

货号：A399066

Adavosertib (AZD-1775; MK-1775) 具有强效的Wee1抑制作用，IC50为5.2 nM。

MK-1775 化学结构
CAS号：955365-80-7

MK-1775 3D分子结构
CAS号：955365-80-7

规格	价格	库存	数量

购物车0 收藏询单

sales@ambeed.cn tech@ambeed.cn 400-920-2911 产品手册产品订购技术咨询
快速发货顺丰冷链运输，1-2 天到达

品质保证

技术支持

免费溶解

MK-1775 纯度/质量文件产品仅供科研

货号：A399066 标准纯度：产品说明书

批次查询：批次纯度: COA NMR HPLC CNMR LC-MS

全球学术期刊中引用的产品: • ACS Appl. Nano Mater., 2025. Ambeed. [ A188026 ]; • Eur. J. Clin. Microbiol. Infect. Dis., 2025. Ambeed. [ A151161 ]; • JJC, 2025, 20(Special Issue)): 27-39. Ambeed. [ A713856 ]; • bioRxiv, 2025. Ambeed. [ A538667 , A714873 , A126729 , A126049 , A446054 ]; • Nature Communications, 2025, 16, 1871. Ambeed. [ A508148 ]; 更多 >

Wee1 亚型比较

产品名称	Wee1 ↓ ↑	纯度
MK-1775	+++ Wee1, IC50: 5.2 nM	98%
PD0166285	++ Wee1, IC50: 24 nM	99%+
1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多，抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用，但抑制强度暂时没有相关数据。

MK-1775 生物活性

靶点

Wee1

Wee1, IC50:5.2 nM

描述

Wee1 is a cellular protein kinase which inhibits Cdc2 activity, thereby preventing cells from proceeding through mitosis by maintaining G2 arrest. MK-1775 (AZD1775) is a first-in-class, pyrazolo-pyrimidine derivative and potent small-molecule inhibitor of Wee1 kinase with IC₅₀ of 5.2 nM and blocks G2 DNA damage checkpoint^[3]. In vitro, MK-1775 treatment at 500 nM for 48h caused S arrest or both S and G2/M arrest in human pancreatic cancer cell lines AsPC-1, BxPC-3, CFPAC-1, HPAC, MIAPaCa-2 and PANC-1^[4]. In vivo, MK-1775 (20 mg/kg) twice daily combined with and panobinostat (10 mg/kg) once daily treatment in mice bearing BxPC-3 xenograft tumors, resulted in significant delay of tumor growth during the treatment period compared to single drug treatment, with 58.7% tumor growth inhibition on day 20^[5]. The combination of gemcitabine (100 mg/kg, i.p., twice weekly on days 1 and 4, for 4 weeks) with MK-1775 (30 mg/kg. p.o., once daily for 4 weeks) produced robust antitumor activity and remarkably enhanced tumor regression response (4.01-fold) compared to gemcitabine treatment in p53-deficient tumors^[6].

MK-1775 细胞研究

细胞系	浓度	检测类型	检测时间	活性说明	数据源
A549	200 nM	Apoptosis Assay	1 h	radiosensitizes NSCLC cells in a p53-dependent manner	21799033
ASPC-1		Growth Inhibition Assay		IC50=13.2 ± 1.1 μM	25458954
BxPC-3		Growth Inhibition Assay		IC50=0.8 ± 0.03 μM	25458954
Calu-6	200 nM	Apoptosis Assay	1 h	radiosensitizes NSCLC cells in a p53-dependent manner	21799033

MK-1775 临床研究

NCT号	适应症或疾病	临床期	招募状态	预计完成时间	地点
NCT03385655	Prostate Cancer	Phase 2	Recruiting	December 31, 2020	Canada, Alberta ... 展开 >> Cross Cancer Institute Recruiting Edmonton, Alberta, Canada, T6G 1Z2 Contact: Michael Kolinsky 780 432-8762 Canada, British Columbia BCCA - Vancouver Cancer Centre Recruiting Vancouver, British Columbia, Canada, V5Z 4E6 Contact: Kim Chi 604 877-6000 ext 2746 Canada, Nova Scotia QEII Health Sciences Centre Recruiting Halifax, Nova Scotia, Canada, B3H 1V7 Contact: Robyn J. Macfarlane 902 473-6106 Canada, Ontario Juravinski Cancer Centre at Hamilton Health Sciences Recruiting Hamilton, Ontario, Canada, L8V 5C2 Contact: Som Mukherjee 905 387-9495 ext 64605 London Regional Cancer Program Recruiting London, Ontario, Canada, N6A 5W9 Contact: Eric W. Winquist 519 685-8261 Ottawa Hospital Research Institute Recruiting Ottawa, Ontario, Canada, K1H 8L6 Contact: Michael Ong 613 737-7700 ext 75051 University Health Network Recruiting Toronto, Ontario, Canada, M5G 2M9 Contact: Adrian Sacher 416 946-4501 ext 3550 Canada, Quebec CHUM-Centre Hospitalier de l'Universite de Montreal Recruiting Montreal, Quebec, Canada, H2X 3E4 Contact: Fred Saad 514 890-8000 ext 27466 The Jewish General Hospital Recruiting Montreal, Quebec, Canada, H3T 1E2 Contact: Cristiano Ferrario 514 398-8307 Canada, Saskatchewan Allan Blair Cancer Centre Recruiting Regina, Saskatchewan, Canada, S4T 7T1 Contact: Muhammad Salim 306 766-2691 Saskatoon Cancer Centre Recruiting Saskatoon, Saskatchewan, Canada, S7N 4H4 Contact: Nayyer Iqbal 306 655-2710 收起 <<
NCT02546661	Muscle Invasive Bladder Cancer	Phase 1	Recruiting	March 27, 2020	-
NCT02813135	Children, Adolescents and Youn... 展开 >>g Adults With Refractory or Recurrent Malignancies 收起 <<	Phase 1 Phase 2	Recruiting	January 2022	France ... 展开 >> Gustave Roussy Recruiting Villejuif, Val De Marne, France, 94805 Contact: Birgit Geoerger, MD 1 42 11 4661 ext +33 birgit.geoerger@gustaveroussy.fr Contact: Xavier Paoletti, MD 1 42 11 6564 ext +33 xavier.paoletti@gustaveroussy.fr Principal Investigator: Birgit Geoerger, MD Germany University Children's Hospitalermany Not yet recruiting Heidelberg, Germany Contact: Olaf Witt, MD 6221 56 4555 ext +49 O.Witt@Dkfz-Heidelberg.de Italy Fondazione IRCCS Istituto Nazionale dei Tumori Not yet recruiting Milan, Italy Contact: Michela Casanova, MD 02 23 90 25 94 ext +39 Michela.Casanova@istitutotumori.mi.it Netherlands Erasmus MC, Sophia Children's Hospital Not yet recruiting Rotterdam, Netherlands Contact: Michel Zwaan, MD 10 703 6691 ext +31 c.m.zwaan@erasmusmc.nl Spain Unidad de Oncología Pediátrica Hospital Niño Jesús Not yet recruiting Madrid, Spain, 28009 Contact: Francisco Bautista, MD 915 035 900 ext +43 franciscojose.bautista@salud.madrid.org United Kingdom Pediatric and Adolescent Oncology The Royal Marsden Hospital Not yet recruiting Sutton, United Kingdom Contact: Lynley Marshall, MD 208 661 3678 ext +44 Lynley.Marshall@icr.ac.uk 收起 <<

MK-1775 参考文献

[1]Do K, Wilsker D, Ji J, Zlott J, Freshwater T, Kinders RJ, Collins J, Chen AP, Doroshow JH, Kummar S. Phase I Study of Single-Agent AZD1775 (MK-1775), a Wee1 Kinase Inhibitor, in Patients With Refractory Solid Tumors. J Clin Oncol. 2015 Oct 20;33(30):3409-15. doi: 10.1200/JCO.2014.60.4009. Epub 2015 May 11. PMID: 25964244; PMCID: PMC4606059.

[2]Wang G, Niu X, Zhang W, Caldwell JT, Edwards H, Chen W, Taub JW, Zhao L, Ge Y. Synergistic antitumor interactions between MK-1775 and panobinostat in preclinical models of pancreatic cancer. Cancer Lett. 2015 Jan 28;356(2 Pt B):656-68. doi: 10.1016/j.canlet.2014.10.015. Epub 2014 Oct 18. PMID: 25458954; PMCID: PMC4282784.

[3]Wang G, Niu X, Zhang W, Caldwell JT, Edwards H, Chen W, Taub JW, Zhao L, Ge Y. Synergistic antitumor interactions between MK-1775 and panobinostat in preclinical models of pancreatic cancer. Cancer Lett. 2015 Jan 28;356(2 Pt B):656-68. doi: 10.1016/j.canlet.2014.10.015. Epub 2014 Oct 18. PMID: 25458954; PMCID: PMC4282784.

[4]Rajeshkumar NV, De Oliveira E, Ottenhof N, Watters J, Brooks D, Demuth T, Shumway SD, Mizuarai S, Hirai H, Maitra A, Hidalgo M. MK-1775, a potent Wee1 inhibitor, synergizes with gemcitabine to achieve tumor regressions, selectively in p53-deficient pancreatic cancer xenografts. Clin Cancer Res. 2011 May 1;17(9):2799-806. doi: 10.1158/1078-0432.CCR-10-2580. Epub 2011 Mar 9. PMID: 21389100; PMCID: PMC3307341.

MK-1775 实验方案

计算器

存储液制备

1mg

5mg

10mg

1 mM

5 mM

10 mM

2.00mL

0.40mL

0.20mL

9.99mL

2.00mL

1.00mL

19.98mL

4.00mL

2.00mL

MK-1775 技术信息

CAS号	955365-80-7
分子式	C₂₇H₃₂N₈O₂
smile	O=C1N(CC=C)N(C2=NC(C(C)(O)C)=CC=C2)C3=NC(NC4=CC=C(N5CCN(C)CC5)C=C4)=NC=C31
MDL No.	MFCD17215200

别名
运输	蓝冰
InChI Key	BKWJAKQVGHWELA-UHFFFAOYSA-N
Pubchem ID	24856436

存储条件

In solvent -20°C:3-6个月-80°C:12个月

Pure form Keep in dark place,Sealed in dry,Store in freezer, under -20°C

溶解方案

细胞实验：

DMSO: 120 mg/mL(239.71 mM)，配合低频超声助溶，注意：DMSO长时间开封后，会吸水并导致溶解能力下降，请避免使用长期开封的DMSO

动物实验：请根据您的动物给药指南选择适当的溶解方案。
以下溶解方案都请先按照体外实验的方式配制澄清的储备液，再依次添加助溶剂：
——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议现用现配，当天使用；以下溶剂前显示的百分比是指该溶剂在终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

方案一

方案二

动物实验配方

IP 2% DMSO+2% Tween80+40% PEG300+water 10 mg/mL clear

PO 0.5% CMC-Na 40 mg/mL suspension

临床研究

NCT号	适应症或疾病	临床期	招募状态	预计完成时间	地点

NCT03385655	Prostate Cancer	Phase 2	Recruiting	December 31, 2020	Canada, Alberta ... 展开 >> Cross Cancer Institute Recruiting Edmonton, Alberta, Canada, T6G 1Z2 Contact: Michael Kolinsky 780 432-8762 Canada, British Columbia BCCA - Vancouver Cancer Centre Recruiting Vancouver, British Columbia, Canada, V5Z 4E6 Contact: Kim Chi 604 877-6000 ext 2746 Canada, Nova Scotia QEII Health Sciences Centre Recruiting Halifax, Nova Scotia, Canada, B3H 1V7 Contact: Robyn J. Macfarlane 902 473-6106 Canada, Ontario Juravinski Cancer Centre at Hamilton Health Sciences Recruiting Hamilton, Ontario, Canada, L8V 5C2 Contact: Som Mukherjee 905 387-9495 ext 64605 London Regional Cancer Program Recruiting London, Ontario, Canada, N6A 5W9 Contact: Eric W. Winquist 519 685-8261 Ottawa Hospital Research Institute Recruiting Ottawa, Ontario, Canada, K1H 8L6 Contact: Michael Ong 613 737-7700 ext 75051 University Health Network Recruiting Toronto, Ontario, Canada, M5G 2M9 Contact: Adrian Sacher 416 946-4501 ext 3550 Canada, Quebec CHUM-Centre Hospitalier de l'Universite de Montreal Recruiting Montreal, Quebec, Canada, H2X 3E4 Contact: Fred Saad 514 890-8000 ext 27466 The Jewish General Hospital Recruiting Montreal, Quebec, Canada, H3T 1E2 Contact: Cristiano Ferrario 514 398-8307 Canada, Saskatchewan Allan Blair Cancer Centre Recruiting Regina, Saskatchewan, Canada, S4T 7T1 Contact: Muhammad Salim 306 766-2691 Saskatoon Cancer Centre Recruiting Saskatoon, Saskatchewan, Canada, S7N 4H4 Contact: Nayyer Iqbal 306 655-2710 收起 <<
NCT02546661	Muscle Invasive Bladder Cancer	Phase 1	Recruiting	March 27, 2020	-
NCT02813135	Children, Adolescents and Youn... 展开 >>g Adults With Refractory or Recurrent Malignancies 收起 <<	Phase 1 Phase 2	Recruiting	January 2022	France ... 展开 >> Gustave Roussy Recruiting Villejuif, Val De Marne, France, 94805 Contact: Birgit Geoerger, MD 1 42 11 4661 ext +33 birgit.geoerger@gustaveroussy.fr Contact: Xavier Paoletti, MD 1 42 11 6564 ext +33 xavier.paoletti@gustaveroussy.fr Principal Investigator: Birgit Geoerger, MD Germany University Children's Hospitalermany Not yet recruiting Heidelberg, Germany Contact: Olaf Witt, MD 6221 56 4555 ext +49 O.Witt@Dkfz-Heidelberg.de Italy Fondazione IRCCS Istituto Nazionale dei Tumori Not yet recruiting Milan, Italy Contact: Michela Casanova, MD 02 23 90 25 94 ext +39 Michela.Casanova@istitutotumori.mi.it Netherlands Erasmus MC, Sophia Children's Hospital Not yet recruiting Rotterdam, Netherlands Contact: Michel Zwaan, MD 10 703 6691 ext +31 c.m.zwaan@erasmusmc.nl Spain Unidad de Oncología Pediátrica Hospital Niño Jesús Not yet recruiting Madrid, Spain, 28009 Contact: Francisco Bautista, MD 915 035 900 ext +43 franciscojose.bautista@salud.madrid.org United Kingdom Pediatric and Adolescent Oncology The Royal Marsden Hospital Not yet recruiting Sutton, United Kingdom Contact: Lynley Marshall, MD 208 661 3678 ext +44 Lynley.Marshall@icr.ac.uk 收起 <<
NCT02465060	Advanced Malignant Solid Neopl... 展开 >>asm Bladder Carcinoma Breast Carcinoma Cervical Carcinoma Colon Carcinoma Colorectal Carcinoma Endometrial Carcinoma Esophageal Carcinoma Gastric Carcinoma Glioma Head and Neck Carcinoma Kidney Carcinoma Liver and Intrahepatic Bile Duct Carcinoma Lung Carcinoma Lymphoma Malignant Uterine Neoplasm Melanoma Ovarian Carcinoma Pancreatic Carcinoma Plasma Cell Myeloma Prostate Carcinoma Rectal Carcinoma Recurrent Bladder Carcinoma Recurrent Breast Carcinoma Recurrent Cervical Carcinoma Recurrent Colon Carcinoma Recurrent Colorectal Carcinoma Recurrent Esophageal Carcinoma Recurrent Gastric Carcinoma Recurrent Glioma Recurrent Head and Neck Carcinoma Recurrent Liver Carcinoma Recurrent Lung Carcinoma Recurrent Lymphoma Recurrent Malignant Solid Neoplasm Recurrent Melanoma Recurrent Ovarian Carcinoma Recurrent Pancreatic Carcinoma Recurrent Plasma Cell Myeloma Recurrent Prostate Carcinoma Recurrent Rectal Carcinoma Recurrent Skin Carcinoma Recurrent Thyroid Gland Carcinoma Recurrent Uterine Corpus Carcinoma Refractory Lymphoma Refractory Malignant Solid Neoplasm Refractory Plasma Cell Myeloma Skin Carcinoma Thyroid Gland Carcinoma Uterine Corpus Cancer 收起 <<	Phase 2	Recruiting	-	-
NCT02937818	Platinum Refractory Extensive-... 展开 >>Stage Small Cell Lung Carcinoma 收起 <<	Phase 2	Recruiting	January 22, 2021	Germany ... 展开 >> Research Site Not yet recruiting Gauting, Germany, 82131 Hungary Research Site Recruiting Kecskemét, Hungary, 6000 Research Site Recruiting Miskolc, Hungary, 3529 Research Site Recruiting Székesfehérvár, Hungary, 8000 Poland Research Site Recruiting Poznań, Poland, 60-569 Research Site Recruiting Warszawa, Poland, 02-781 Spain Research Site Recruiting Sevilla, Spain, 41009 Research Site Recruiting Valencia, Spain, 46009 Ukraine Research Site Recruiting Dnipropetrovsk, Ukraine, 49102 Research Site Recruiting Ivano-Frankivsk, Ukraine, 76018 Research Site Not yet recruiting Kirovograd, Ukraine, 25006 Research Site Active, not recruiting Sumy, Ukraine, 40022 收起 <<
NCT01827384	Advanced Malignant Solid Neopl... 展开 >>asm 收起 <<	Not Applicable	Suspended(Scheduled Interim Mo... 展开 >>nitoring) 收起 <<	-	United States, Colorado ... 展开 >> University of Colorado Hospital Aurora, Colorado, United States, 80045 United States, Kentucky University of Kentucky/Markey Cancer Center Lexington, Kentucky, United States, 40536 United States, Maryland National Cancer Institute Developmental Therapeutics Clinic Bethesda, Maryland, United States, 20892 United States, Missouri Washington University School of Medicine Saint Louis, Missouri, United States, 63110 United States, New Jersey Rutgers Cancer Institute of New Jersey New Brunswick, New Jersey, United States, 08903 United States, Pennsylvania University of Pittsburgh Cancer Institute (UPCI) Pittsburgh, Pennsylvania, United States, 15232 United States, Texas M D Anderson Cancer Center Houston, Texas, United States, 77030 收起 <<
NCT03579316	Recurrent Fallopian Tube Carci... 展开 >>noma Recurrent Ovarian Carcinoma Recurrent Primary Peritoneal Carcinoma 收起 <<	Phase 2	Recruiting	March 31, 2019	United States, Massachusetts ... 展开 >> Dana Farber Cancer Institute Recruiting Boston, Massachusetts, United States, 02215 United States, Texas M D Anderson Cancer Center Recruiting Houston, Texas, United States, 77030 Contact: Robert L. Coleman 713-745-3357 Principal Investigator: Robert L. Coleman 收起 <<
NCT03345784	Endometrioid Adenocarcinoma ... 展开 >> Recurrent Cervical Carcinoma Stage I Uterine Corpus Cancer AJCC v7 Stage I Vaginal Cancer AJCC v6 and v7 Stage IA Uterine Corpus Cancer AJCC v7 Stage IB Cervical Cancer AJCC v6 and v7 Stage IB Uterine Corpus Cancer AJCC v7 Stage IB2 Cervical Cancer AJCC v6 and v7 Stage II Cervical Cancer AJCC v7 Stage II Uterine Corpus Cancer AJCC v7 Stage II Vaginal Cancer AJCC v6 and v7 Stage IIA Cervical Cancer AJCC v7 Stage IIB Cervical Cancer AJCC v6 and v7 Stage III Cervical Cancer AJCC v6 and v7 Stage III Uterine Corpus Cancer AJCC v7 Stage III Vaginal Cancer AJCC v6 and v7 Stage IIIA Cervical Cancer AJCC v6 and v7 Stage IIIA Uterine Corpus Cancer AJCC v7 Stage IIIB Cervical Cancer AJCC v6 and v7 Stage IIIB Uterine Corpus Cancer AJCC v7 Stage IIIC Uterine Corpus Cancer AJCC v7 收起 <<	Phase 1	Recruiting	October 18, 2020	United States, California ... 展开 >> University of California Davis Comprehensive Cancer Center Recruiting Sacramento, California, United States, 95817 Contact: Site Public Contact 916-734-3089 Principal Investigator: Vanessa A. Kennedy United States, Colorado University of Colorado Hospital Recruiting Aurora, Colorado, United States, 80045 Contact: Site Public Contact 720-848-0650 Principal Investigator: Bradley R. Corr United States, Kentucky University of Kentucky/Markey Cancer Center Recruiting Lexington, Kentucky, United States, 40536 Contact: Site Public Contact 859-257-3379 Principal Investigator: Rachel W. Miller United States, New Jersey Rutgers Cancer Institute of New Jersey-Robert Wood Johnson University Hospital Recruiting New Brunswick, New Jersey, United States, 08903 Contact: Site Public Contact 732-235-8675 Principal Investigator: Eugenia Girda Rutgers Cancer Institute of New Jersey Recruiting New Brunswick, New Jersey, United States, 08903 Contact: Site Public Contact 732-235-8675 Principal Investigator: Eugenia Girda United States, North Carolina Duke University Medical Center Recruiting Durham, North Carolina, United States, 27710 Contact: Site Public Contact 888-275-3853 Principal Investigator: James L. Abbruzzese Canada, Ontario University Health Network-Princess Margaret Hospital Recruiting Toronto, Ontario, Canada, M5G 2M9 Contact: Site Public Contact 416-946-4501 clinical.trials@uhn.on.ca Principal Investigator: Stephanie Lheureux 收起 <<
NCT03284385	Locally Advanced Malignant Sol... 展开 >>id Neoplasm Metastatic Malignant Solid Neoplasm 收起 <<	Phase 2	Recruiting	August 30, 2021	United States, California ... 展开 >> University of California Davis Comprehensive Cancer Center Recruiting Sacramento, California, United States, 95817 Contact: Site Public Contact 916-734-3089 Principal Investigator: Mamta Parikh UCSF Medical Center-Mount Zion Recruiting San Francisco, California, United States, 94115 Contact: Site Public Contact 877-827-3222 Principal Investigator: Rahul R. Aggarwal UCSF Medical Center-Mission Bay Recruiting San Francisco, California, United States, 94158 Contact: Site Public Contact 877-827-3222 Principal Investigator: Rahul R. Aggarwal United States, District of Columbia MedStar Georgetown University Hospital Recruiting Washington, District of Columbia, United States, 20007 Contact: Site Public Contact 202-444-2223 Principal Investigator: Michael J. Pishvaian United States, Maryland Johns Hopkins University/Sidney Kimmel Cancer Center Recruiting Baltimore, Maryland, United States, 21287 Contact: Site Public Contact 410-955-8804 jhcccro@jhmi.edu Principal Investigator: Ana D. De Jesus Acosta United States, Massachusetts Massachusetts General Hospital Cancer Center Recruiting Boston, Massachusetts, United States, 02114 Contact: Site Public Contact 877-726-5130 Principal Investigator: Geoffrey I. Shapiro Brigham and Women's Hospital Recruiting Boston, Massachusetts, United States, 02115 Contact: Site Public Contact 888-823-5923 ctsucontact@westat.com Principal Investigator: Geoffrey I. Shapiro Beth Israel Deaconess Medical Center Recruiting Boston, Massachusetts, United States, 02215 Contact: Site Public Contact 617-667-9925 Principal Investigator: Geoffrey I. Shapiro Dana-Farber Cancer Institute Recruiting Boston, Massachusetts, United States, 02215 Contact: Site Public Contact 877-442-3324 Principal Investigator: Geoffrey I. Shapiro United States, Missouri Siteman Cancer Center at West County Hospital Recruiting Creve Coeur, Missouri, United States, 63141 Contact: Site Public Contact 800-600-3606 info@siteman.wustl.edu Principal Investigator: Nikolaos Trikalinos Washington University School of Medicine Recruiting Saint Louis, Missouri, United States, 63110 Contact: Site Public Contact 800-600-3606 info@siteman.wustl.edu Principal Investigator: Nikolaos Trikalinos Siteman Cancer Center-South County Recruiting Saint Louis, Missouri, United States, 63129 Contact: Site Public Contact 800-600-3606 info@siteman.wustl.edu Principal Investigator: Nikolaos Trikalinos Siteman Cancer Center at Christian Hospital Recruiting Saint Louis, Missouri, United States, 63136 Contact: Site Public Contact 800-600-3606 info@siteman.wustl.edu Principal Investigator: Nikolaos Trikalinos Siteman Cancer Center at Saint Peters Hospital Recruiting Saint Peters, Missouri, United States, 63376 Contact: Site Public Contact 800-600-3606 info@siteman.wustl.edu Principal Investigator: Nikolaos Trikalinos United States, Pennsylvania University of Pittsburgh Cancer Institute (UPCI) Recruiting Pittsburgh, Pennsylvania, United States, 15232 Contact: Site Public Contact 412-647-8073 Principal Investigator: Nathan Bahary United States, Tennessee Vanderbilt University/Ingram Cancer Center Recruiting Nashville, Tennessee, United States, 37232 Contact: Site Public Contact 800-811-8480 Principal Investigator: W. K. Rathmell 收起 <<
NCT02095132	Central Nervous System Embryon... 展开 >>al Tumor With Rhabdoid Features Central Nervous System Embryonal Tumor, Not Otherwise Specified Central Nervous System Ganglioneuroblastoma Embryonal Tumor With Multilayered Rosettes, C19MC-Altered Pineoblastoma Primary Central Nervous System Neoplasm Recurrent Childhood Central Nervous System Embryonal Neoplasm Recurrent Malignant Solid Neoplasm Recurrent Medulloblastoma Recurrent Neuroblastoma Recurrent Rhabdomyosarcoma Refractory Malignant Solid Neoplasm Refractory Medulloblastoma Refractory Neuroblastoma Refractory Rhabdomyosarcoma 收起 <<	Phase 1 Phase 2	Recruiting	-	-
NCT03330847	Metastatic Triple Negative Bre... 展开 >>ast Cancer 收起 <<	Phase 2	Recruiting	January 20, 2021	-
NCT02576444	Cancer	Phase 2	Recruiting	March 2019	United States, Connecticut ... 展开 >> Yale Cancer Center Recruiting New Haven, Connecticut, United States, 06520-8028 Contact: Alexandra Minnella 203-737-3446 alexandra.minnella@yale.edu Principal Investigator: Joseph P Eder, MD United States, Massachusetts Dana-Farber Cancer Institute Recruiting Boston, Massachusetts, United States, 02215 Contact: Brian Beardslee 617-632-5638 brian_beardslee@dfci.harvard.edu Principal Investigator: Geoffrey Shapiro, MD United States, Ohio Cleveland Clinic Taussig Cancer Institute Recruiting Cleveland, Ohio, United States, 44195 Contact: Nancy Frazier 216-444-5531 frazien@ccf.org Principal Investigator: Davendra PS Sohal, MD, MPH United States, Tennessee Vanderbilt-Ingram Cancer Center Recruiting Nashville, Tennessee, United States, 37232 Contact: Tom Leonard-Martin 615-936-6726 Thomas.Leonard-Martin@vumc.org Principal Investigator: Vicki L Keedy, MD 收起 <<
NCT02659241	Ovarian Cancer ... 展开 >> Fallopian Tube Cancer Peritoneum Cancer 收起 <<	Early Phase 1	Recruiting	February 2021	United States, Texas ... 展开 >> University of Texas MD Anderson Cancer Center Recruiting Houston, Texas, United States, 77030 收起 <<
NCT02448329	Advanced Gastric Adenocarcinom... 展开 >>a 收起 <<	Phase 2	Recruiting	December 2019	Korea, Republic of ... 展开 >> Samsung Medical center Recruiting Seoul, Korea, Republic of, 135-710 Contact: Yoonjeong Ahn 82-2-2148-7395 younjeong.ahn@samsung.com Principal Investigator: Jeeyun Lee, MD,PhD 收起 <<
NCT01849146	Adult Glioblastoma ... 展开 >> Recurrent Glioblastoma 收起 <<	Phase 1	Recruiting	-	United States, Alabama ... 展开 >> University of Alabama at Birmingham Cancer Center Suspended Birmingham, Alabama, United States, 35233 United States, California UCLA / Jonsson Comprehensive Cancer Center Suspended Los Angeles, California, United States, 90095 UCSF Medical Center-Parnassus Suspended San Francisco, California, United States, 94143 United States, Maryland Johns Hopkins University/Sidney Kimmel Cancer Center Suspended Baltimore, Maryland, United States, 21287 United States, Massachusetts Massachusetts General Hospital Cancer Center Recruiting Boston, Massachusetts, United States, 02114 Contact: Site Public Contact 877-726-5130 Principal Investigator: Eudocia Q. Lee Dana-Farber Cancer Institute Recruiting Boston, Massachusetts, United States, 02215 Contact: Site Public Contact 877-442-3324 Principal Investigator: Eudocia Q. Lee United States, Michigan Henry Ford Hospital Recruiting Detroit, Michigan, United States, 48202 Contact: Site Public Contact 313-916-1784 Principal Investigator: Tobias Walbert United States, New York Memorial Sloan Kettering Cancer Center Suspended New York, New York, United States, 10065 United States, North Carolina Wake Forest University Health Sciences Recruiting Winston-Salem, North Carolina, United States, 27157 Contact: Site Public Contact 336-713-6771 Principal Investigator: Glenn J. Lesser United States, Ohio Cleveland Clinic Foundation Suspended Cleveland, Ohio, United States, 44195 United States, Pennsylvania University of Pennsylvania/Abramson Cancer Center Suspended Philadelphia, Pennsylvania, United States, 19104 University of Pittsburgh Cancer Institute (UPCI) Suspended Pittsburgh, Pennsylvania, United States, 15232 收起 <<
NCT02666950	Chronic Myelomonocytic Leukemi... 展开 >>a Myelodysplastic Syndrome With Isolated Del(5q) Myelodysplastic/Myeloproliferative Neoplasm Previously Treated Myelodysplastic Syndrome Recurrent Adult Acute Myeloid Leukemia Untreated Adult Acute Myeloid Leukemia 收起 <<	Phase 2	Completed	-	United States, Arizona ... 展开 >> Mayo Clinic in Arizona Scottsdale, Arizona, United States, 85259 收起 <<
NCT02906059	Metastatic Colorectal Cancer	Phase 1	Recruiting	September 2019	United States, New York ... 展开 >> Laura and Isaac Perlmutter Cancer Center Recruiting New York, New York, United States, 10016 Contact: Deirdre Cohen, MD 212-731-5656 Deirdre.Cohen@nyumc.org Sub-Investigator: Ping Gu, MD Sub-Investigator: Cynthia Leichman, MD Sub-Investigator: Lawrence Leichman, MD Sub-Investigator: Theresa Ryan, MD Sub-Investigator: Jennifer Wu, MD 收起 <<
NCT02272790	Ovarian, Fallopian Tube, Perit... 展开 >>oneal Cancer, P53 Mutation 收起 <<	Phase 2	Active, not recruiting	December 17, 2018	United States, Arizona ... 展开 >> Research Site Gilbert, Arizona, United States, 85234 Research Site Tucson, Arizona, United States, 85724 United States, California Research Site La Jolla, California, United States, 92093 Research Site Los Angeles, California, United States, 90095-6996 Research Site San Francisco, California, United States, 94158 United States, Florida Research Site Tampa, Florida, United States, 33612 Research Site West Palm Beach, Florida, United States, 33401 United States, Georgia Research Site Augusta, Georgia, United States, 30912 United States, Massachusetts Research Site Boston, Massachusetts, United States, 02215 United States, New York Research Site New York, New York, United States, 10019 Research Site New York, New York, United States, 10065 United States, Ohio Research Site Cleveland, Ohio, United States, 44195 United States, Oklahoma Research Site Oklahoma City, Oklahoma, United States, 73104 United States, Tennessee Research Site Nashville, Tennessee, United States, 37203 United States, Texas Research Site Dallas, Texas, United States, 75390 United States, Wisconsin Research Site Milwaukee, Wisconsin, United States, 53226 Canada, Ontario Research Site Toronto, Ontario, Canada, M5G 2M9 Netherlands Research Site Amsterdam, Netherlands, 1066 CX 收起 <<
NCT03028766	Hypopharynx Squamous Cell Carc... 展开 >>inoma Oral Cavity Squamous Cell Carcinoma Larynx Cancer 收起 <<	Phase 1	Recruiting	December 2019	United Kingdom ... 展开 >> University Hospital Birmingham Nhs Foundation Trust Recruiting Birmingham, West Midlands, United Kingdom, B15 2TH Principal Investigator: James Good Beatson West of Scotland Cancer Centre Recruiting Glasgow, United Kingdom, G12 0YN Principal Investigator: Stefano Schipani University College London Hospitals Recruiting London, United Kingdom, W1T 7HA Principal Investigator: Martin Forster Clatterbridge Cancer Centre Not yet recruiting Wirral, United Kingdom, CH63 4JY Principal Investigator: Joseph Sacco 收起 <<
NCT03718143	Myelofibroses ... 展开 >> Acute Myeloid Leukemia Myelodysplastic Syndromes 收起 <<	Phase 2	Not yet recruiting	May 1, 2021	-
NCT02617277	Advanced Solid Tumours	Phase 1	Recruiting	April 8, 2019	United States, Colorado ... 展开 >> Research Site Recruiting Denver, Colorado, United States, 80218 United States, Florida Research Site Recruiting Sarasota, Florida, United States, 34232 United States, Tennessee Research Site Recruiting Nashville, Tennessee, United States, 37203 收起 <<
NCT03253679	Advanced Malignant Solid Neopl... 展开 >>asm CCNE1 Gene Amplification Refractory Malignant Solid Neoplasm 收起 <<	Phase 2	Recruiting	September 30, 2020	United States, Colorado ... 展开 >> University of Colorado Hospital Recruiting Aurora, Colorado, United States, 80045 Contact: Site Public Contact 720-848-0650 Principal Investigator: Brandon D. Bernard United States, New York Columbia University/Herbert Irving Cancer Center Recruiting New York, New York, United States, 10032 Contact: Site Public Contact 212-305-6361 nr2616@cumc.columbia.edu Principal Investigator: Richard D. Carvajal United States, North Carolina Duke University Medical Center Recruiting Durham, North Carolina, United States, 27710 Contact: Site Public Contact 888-275-3853 Principal Investigator: James L. Abbruzzese United States, Texas M D Anderson Cancer Center Recruiting Houston, Texas, United States, 77030 Contact: Site Public Contact 877-312-3961 Principal Investigator: Siqing Fu 收起 <<
NCT03333824	Solid Tumours	Phase 1	Recruiting	June 28, 2019	United States, Arizona ... 展开 >> Research Site Withdrawn Tucson, Arizona, United States, 85724 United States, California Research Site Withdrawn Los Angeles, California, United States, 90048 Research Site Withdrawn Pasadena, California, United States, 91105 United States, Indiana Research Site Not yet recruiting Indianapolis, Indiana, United States, 46202 United States, Maryland Research Site Withdrawn Silver Spring, Maryland, United States, 20910 United States, Michigan Research Site Recruiting Bingham Farms, Michigan, United States, 48025 Research Site Recruiting Detroit, Michigan, United States, 48202 United States, New Hampshire Research Site Recruiting Lebanon, New Hampshire, United States, 03756 United States, Ohio Research Site Recruiting Cincinnati, Ohio, United States, 45229 United States, Rhode Island Research Site Recruiting Providence, Rhode Island, United States, 02903 United States, South Carolina Research Site Recruiting Greenville, South Carolina, United States, 29605 United States, Texas Research Site Recruiting Dallas, Texas, United States, 75251 Research Site Withdrawn Houston, Texas, United States, 77030 收起 <<
NCT02381548	Acute Myeloid Leukemia ... 展开 >> Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive Myelodysplastic Syndrome Previously Treated Myelodysplastic Syndrome Recurrent Adult Acute Myeloid Leukemia Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive Refractory Acute Myeloid Leukemia Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive Secondary Acute Myeloid Leukemia Therapy-Related Acute Myeloid Leukemia Untreated Adult Acute Myeloid Leukemia 收起 <<	Phase 1	Terminated	-	United States, Florida ... 展开 >> Moffitt Cancer Center Tampa, Florida, United States, 33612 United States, Virginia Virginia Commonwealth University/Massey Cancer Center Richmond, Virginia, United States, 23298 收起 <<
NCT02194829	Metastatic Pancreatic Adenocar... 展开 >>cinoma Stage III Pancreatic Cancer AJCC v6 and v7 Stage IV Pancreatic Cancer AJCC v6 and v7 Unresectable Pancreatic Carcinoma 收起 <<	Phase 1 Phase 2	Active, not recruiting	-	United States, Illinois ... 展开 >> Northwestern University Chicago, Illinois, United States, 60611 United States, Ohio Case Western Reserve University Cleveland, Ohio, United States, 44106 United States, Pennsylvania University of Pennsylvania/Abramson Cancer Center Philadelphia, Pennsylvania, United States, 19104 Fox Chase Cancer Center Philadelphia, Pennsylvania, United States, 19111 United States, Tennessee Vanderbilt University/Ingram Cancer Center Nashville, Tennessee, United States, 37232 收起 <<
NCT01922076	Anaplastic Astrocytoma ... 展开 >> Anaplastic Oligoastrocytoma Diffuse Intrinsic Pontine Glioma Diffuse Midline Glioma, H3 K27M-Mutant Glioblastoma Gliosarcoma Untreated Childhood Anaplastic Astrocytoma Untreated Childhood Anaplastic Oligoastrocytoma Untreated Childhood Glioblastoma Untreated Childhood Gliosarcoma 收起 <<	Phase 1	Recruiting	-	-
NCT02791919	CNS 2a CNS 2b... 展开 >> CNS 2c CNS1 Recurrent Adult Acute Myeloid Leukemia Recurrent Childhood Acute Myeloid Leukemia 收起 <<	Phase 1	Withdrawn(Other - Protocol mov... 展开 >>ed to Disapproved) 收起 <<	May 31, 2019	-
NCT03012477	Triple-negative Metastatic Bre... 展开 >>ast Cancer 收起 <<	Phase 2	Recruiting	December 2024	United States, Massachusetts ... 展开 >> Massachusetts General Hospital Recruiting Boston, Massachusetts, United States, 02114 Contact: Steven Isakoff, MD, PhD Contact 617-726-4920 sisakoff@partners.org Dana-Farber Cancer Institute Recruiting Boston, Massachusetts, United States, 02215 Contact: Sara Tolaney, MD, MPH 617-632-3800 stolaney@partners.org Principal Investigator: Sara Tolaney, MD, MPH 收起 <<
NCT02513563	Lung Cancer	Phase 2	Recruiting	October 2020	United States, Florida ... 展开 >> H. Lee Moffitt Cancer Center and Research Institute Recruiting Tampa, Florida, United States, 33612 Contact: Germaine Gonzalez-Vazquez 813-745-6636 germaine.gonzalezvazquez@moffitt.org Contact: Jhanelle Gray, M.D. 813-745-7282 jhanelle.gray@moffitt.org Principal Investigator: Jhanelle Gray, M.D. Sub-Investigator: Scott Antonia, M.D., Ph.D. Sub-Investigator: Alberto Chiappori, M.D. Sub-Investigator: Ben Creelan, M.D. Sub-Investigator: Eric Haura, M.D. Sub-Investigator: Tawee Tanvetyanon, M.D. Sub-Investigator: Charles Williams, M.D. Sub-Investigator: Trevor Rose, M.D. 收起 <<
NCT00648648	Solid Tumors	Phase 1	Completed	-	-
NCT03313557	Solid Tumors	Phase 1	Recruiting	August 11, 2020	United States, Arizona ... 展开 >> Research Site Withdrawn Tucson, Arizona, United States, 85724 United States, California Research Site Withdrawn Los Angeles, California, United States, 90048 Research Site Withdrawn Pasadena, California, United States, 91105 United States, Maryland Research Site Withdrawn Silver Spring, Maryland, United States, 20910 United States, Michigan Research Site Recruiting Bingham Farms, Michigan, United States, 48025 Research Site Recruiting Detroit, Michigan, United States, 48202 United States, New Hampshire Research Site Recruiting Lebanon, New Hampshire, United States, 03756 United States, Ohio Research Site Recruiting Cincinnati, Ohio, United States, 45229 United States, Rhode Island Research Site Recruiting Providence, Rhode Island, United States, 02906 United States, South Carolina Research Site Recruiting Greenville, South Carolina, United States, 29605 United States, Texas Research Site Recruiting Dallas, Texas, United States, 75251 Research Site Withdrawn Houston, Texas, United States, 77030 France Research Site Completed Bordeaux Cedex, France, 33075 Research Site Completed Saint Herblain Cedex, France, 44805 Netherlands Research Site Active, not recruiting Amsterdam, Netherlands, 1066 CX Research Site Active, not recruiting Amsterdam, Netherlands, 1081 HV Research Site Active, not recruiting Maastricht, Netherlands, 6229 HX United Kingdom Research Site Active, not recruiting Glasgow, United Kingdom, G12 0YN Research Site Active, not recruiting Manchester, United Kingdom, M20 4BX 收起 <<
NCT03315091	Solid Tumours	Phase 1	Completed	-	France ... 展开 >> Research Site Bordeaux Cedex, France, 33075 Research Site Saint Herblain, France, 44805 Netherlands Research Site Amsterdam, Netherlands, 1066 CX Research Site Amsterdam, Netherlands, 1081 HV Research Site Maastricht, Netherlands, 6229 HX United Kingdom Research Site Glasgow, United Kingdom, G12 0YN Research Site Manchester, United Kingdom, M20 4BX 收起 <<
NCT02585973	Carcinoma, Squamous Cell of He... 展开 >>ad and Neck 收起 <<	Phase 1	Recruiting	November 2021	United States, North Carolina ... 展开 >> UNC Lineberger Comprehensive Cancer Center Recruiting Chapel Hill, North Carolina, United States, 27599 Contact: Dan Goldin 919-966-4432 dan_goldin@med.unc.edu Contact: Chris Hilliard 919-966-4432 Chris_Hilliard@med.unc.edu 收起 <<
NCT02593019	Small Cell Lung Cancer	Phase 2	Active, not recruiting	March 2019	Korea, Republic of ... 展开 >> Samsung Medical Center Seoul, Korea, Republic of, 135-710 收起 <<
NCT03668340	Uterine Cancer	Phase 2	Recruiting	June 1, 2023	United States, Massachusetts ... 展开 >> Massachusetts General Hospital Cancer Center Not yet recruiting Boston, Massachusetts, United States, 02214 Contact: Richard T Penson, MD rpenson@partners.org Principal Investigator: Richard T Penson, MD Dana Farber Cancer Institute Recruiting Boston, Massachusetts, United States, 02215 Contact: Joyce Liu, MD joyce_liu@dfci.harvard.edu Principal Investigator: Joyce Liu, MD 收起 <<
NCT02511795	Refractory Solid Tumours ... 展开 >> Relapsed Small Cell Lung Cancer (SCLC) 收起 <<	Phase 1	Recruiting	September 27, 2019	United States, Colorado ... 展开 >> Research Site Recruiting Denver, Colorado, United States, 80218 United States, Florida Research Site Recruiting Sarasota, Florida, United States, 34232 United States, New York Research Site Recruiting New York, New York, United States, 10033 United States, Tennessee Research Site Recruiting Nashville, Tennessee, United States, 37203 United States, Texas Research Site Recruiting Houston, Texas, United States, 77030 Canada, Ontario Research Site Active, not recruiting Toronto, Ontario, Canada, M5G 2M9 收起 <<
NCT02087176	-		Terminated(The study was termi... 展开 >>nated early by the sponsor.) 收起 <<	-	-
NCT02688907	Small Cell Lung Cancer	Phase 2	Terminated(change regimen)	-	Korea, Republic of ... 展开 >> Keunchil Park Seoul, Korea, Republic of, 135-710 收起 <<
NCT02482311	Ovarian Cancer, TNBC, SCLC, Ot... 展开 >>her Solid Tumours 收起 <<	Phase 1	Active, not recruiting	October 1, 2018	United States, Arkansas ... 展开 >> Research Site Fayetteville, Arkansas, United States, 72703 United States, California Research Site La Jolla, California, United States, 92093 Research Site Los Angeles, California, United States, 90048 Research Site San Francisco, California, United States, 94115 United States, Florida Research Site Fort Myers, Florida, United States, 33905 United States, Indiana Research Site Indianapolis, Indiana, United States, 46202 United States, Michigan Research Site Detroit, Michigan, United States, 48201 United States, North Carolina Research Site Charlotte, North Carolina, United States, 28204 United States, Oklahoma Research Site Oklahoma City, Oklahoma, United States, 73104 United States, Pennsylvania Research Site Philadelphia, Pennsylvania, United States, 19104 United States, South Carolina Research Site Greenville, South Carolina, United States, 29605 United States, Tennessee Research Site Nashville, Tennessee, United States, 37203 United States, Texas Research Site Houston, Texas, United States, 77030 United States, Wisconsin Research Site Milwaukee, Wisconsin, United States, 53226 Canada, Alberta Research Site Edmonton, Alberta, Canada, T6G 1Z2 Canada, British Columbia Research Site Vancouver, British Columbia, Canada, V5Z 4E6 Canada, Ontario Research Site Toronto, Ontario, Canada, M5G 2M9 收起 <<
NCT02101775	Ovarian Brenner Tumor ... 展开 >> Ovarian Carcinosarcoma Ovarian Clear Cell Cystadenocarcinoma Ovarian Endometrioid Adenocarcinoma Ovarian Mucinous Cystadenocarcinoma Ovarian Seromucinous Carcinoma Ovarian Serous Cystadenocarcinoma Ovarian Serous Surface Papillary Adenocarcinoma Ovarian Undifferentiated Carcinoma Recurrent Fallopian Tube Carcinoma Recurrent Ovarian Carcinoma Recurrent Primary Peritoneal Carcinoma 收起 <<	Phase 2	Active, not recruiting	-	United States, California ... 展开 >> City of Hope Comprehensive Cancer Center Duarte, California, United States, 91010 City of Hope South Pasadena South Pasadena, California, United States, 91030 United States, Illinois University of Chicago Comprehensive Cancer Center Chicago, Illinois, United States, 60637 Decatur Memorial Hospital Decatur, Illinois, United States, 62526 United States, Indiana Indiana University/Melvin and Bren Simon Cancer Center Indianapolis, Indiana, United States, 46202 United States, Minnesota Mayo Clinic Rochester, Minnesota, United States, 55905 United States, Pennsylvania Fox Chase Cancer Center Philadelphia, Pennsylvania, United States, 19111 University of Pittsburgh Cancer Institute (UPCI) Pittsburgh, Pennsylvania, United States, 15232 Canada, British Columbia BCCA-Cancer Centre for the Southern Interior Kelowna, British Columbia, Canada, V1Y 5L3 BCCA-Vancouver Cancer Centre Vancouver, British Columbia, Canada, V5Z 4E6 Canada, Ontario London Regional Cancer Program London, Ontario, Canada, N6A 4L6 Ottawa Hospital and Cancer Center-General Campus Ottawa, Ontario, Canada, K1H 8L6 University Health Network Princess Margaret Cancer Center P2C Toronto, Ontario, Canada, M5G 2M9 University Health Network-Princess Margaret Hospital Toronto, Ontario, Canada, M5G 2M9 Canada, Quebec CHUM - Hopital Notre-Dame Montreal, Quebec, Canada, H2L 4M1 Singapore National University Hospital Singapore Singapore, Singapore, 119074 收起 <<
NCT02087241	Previously Untreated Stage IV ... 展开 >>Non-Squamous Non Small Cell Lung Cancer 收起 <<	Phase 2	Terminated(The sponsor decided... 展开 >> to terminate the study.) 收起 <<	-	United States, Colorado ... 展开 >> Research Site Englewood, Colorado, United States United States, Florida Research Site Fort Myers, Florida, United States Research Site Orlando, Florida, United States United States, Illinois Research Site Peoria, Illinois, United States United States, Indiana Research Site Fort Wayne, Indiana, United States United States, Kansas Research Site Wichita, Kansas, United States United States, Ohio Research Site Cincinnati, Ohio, United States United States, Tennessee Research Site Nashville, Tennessee, United States 收起 <<
NCT02087241	-		Terminated(The sponsor decided... 展开 >> to terminate the study.) 收起 <<	-	-
NCT02087176	Previously Treated Non Small C... 展开 >>ell Lung Cancer 收起 <<	Phase 2	Terminated(The study was termi... 展开 >>nated early by the sponsor.) 收起 <<	-	United States, Alabama ... 展开 >> Research Site Birmingham, Alabama, United States United States, Arizona Research Site Scottsdale, Arizona, United States United States, Arkansas Research Site Fayetteville, Arkansas, United States United States, Colorado Research Site Englewood, Colorado, United States United States, Florida Research Site Orlando, Florida, United States United States, Kansas Research Site Wichita, Kansas, United States United States, Kentucky Research Site Louisville, Kentucky, United States United States, North Carolina Research Site Durham, North Carolina, United States United States, Ohio Research Site Cincinnati, Ohio, United States United States, Pennsylvania Research Site Pittsburgh, Pennsylvania, United States United States, Tennessee Research Site Nashville, Tennessee, United States United States, Wisconsin Research Site Milwaukee, Wisconsin, United States 收起 <<
NCT02610075	Locally Advanced Solid Tumours... 展开 >> Metastatic Solid Tumours Ovarian Cancer 收起 <<	Phase 1	Completed	-	United States, Arizona ... 展开 >> Research Site Scottsdale, Arizona, United States, 85258 United States, Colorado Research Site Denver, Colorado, United States, 80218 United States, Tennessee Research Site Nashville, Tennessee, United States, 32705 收起 <<
NCT02207010	Glioblastoma ... 展开 >>GBM 收起 <<	Early Phase 1	Active, not recruiting	May 2018	United States, Arizona ... 展开 >> Barrow Neurological Institute at St. Joseph's Hospital Medical Center Phoenix, Arizona, United States, 85013 收起 <<
NCT02196168	Recurrent Hypopharyngeal Squam... 展开 >>ous Cell Carcinoma Recurrent Laryngeal Squamous Cell Carcinoma Recurrent Laryngeal Verrucous Carcinoma Recurrent Lip and Oral Cavity Squamous Cell Carcinoma Recurrent Metastatic Squamous Cell Carcinoma in the Neck With Occult Primary Recurrent Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma Recurrent Oral Cavity Verrucous Carcinoma Recurrent Oropharyngeal Squamous Cell Carcinoma Squamous Cell Carcinoma Metastatic in the Neck With Occult Primary Stage IV Hypopharyngeal Squamous Cell Carcinoma Stage IVA Laryngeal Squamous Cell Carcinoma Stage IVA Laryngeal Verrucous Carcinoma Stage IVA Lip and Oral Cavity Squamous Cell Carcinoma Stage IVA Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma Stage IVA Oral Cavity Verrucous Carcinoma Stage IVA Oropharyngeal Squamous Cell Carcinoma Stage IVB Laryngeal Squamous Cell Carcinoma Stage IVB Laryngeal Verrucous Carcinoma Stage IVB Lip and Oral Cavity Squamous Cell Carcinoma Stage IVB Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma Stage IVB Oral Cavity Verrucous Carcinoma Stage IVB Oropharyngeal Squamous Cell Carcinoma Stage IVC Laryngeal Squamous Cell Carcinoma Stage IVC Laryngeal Verrucous Carcinoma Stage IVC Lip and Oral Cavity Squamous Cell Carcinoma Stage IVC Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma Stage IVC Oral Cavity Verrucous Carcinoma Stage IVC Oropharyngeal Squamous Cell Carcinoma Tongue Carcinoma 收起 <<	Phase 2	Terminated(Inadequate accrual ... 展开 >>rate) 收起 <<	-	Canada, Ontario ... 展开 >> Juravinski Cancer Centre at Hamilton Health Sciences Hamilton, Ontario, Canada, L8V 5C2 London Regional Cancer Program London, Ontario, Canada, N6A 4L6 University Health Network-Princess Margaret Hospital Toronto, Ontario, Canada, M5G 2M9 收起 <<
NCT02508246	Head and Neck Squamous Cell Ca... 展开 >>rcinoma 收起 <<	Phase 1	Active, not recruiting	-	United States, Washington ... 展开 >> Fred Hutch/University of Washington Cancer Consortium Seattle, Washington, United States, 98109 收起 <<
NCT02196168	-		Terminated(Inadequate accrual ... 展开 >>rate) 收起 <<	-	-
NCT01357161	Ovarian Cancer	Phase 2	Completed	-	-
NCT02341456	Advanced Solid Tumours	Phase 1	Completed	-	Australia ... 展开 >> Research Site Liverpool, Australia, 2170 Research Site Melbourne, Australia, 3004 Japan Research Site Kashiwa, Japan, 277-8577 Research Site Sapporo-shi, Japan, 003-0804 Korea, Republic of Research Site Seoul, Korea, Republic of, 03080 Research Site Seoul, Korea, Republic of, 05505 Research Site Seoul, Korea, Republic of, 06351 收起 <<
NCT01357161	-		Completed	-	-
NCT01076400	Cervical Cancer	Phase 1 Phase 2	Terminated(The sponsor permane... 展开 >>ntly suspended new enrollment into the trial and discontinued the study; which was not related to any concerns over product safety.) 收起 <<	-	-
NCT02037230	Adenocarcinoma of the Pancreas	Phase 1 Phase 2	Active, not recruiting	January 2022	United States, Michigan ... 展开 >> University of Michigan Hospital Ann Arbor, Michigan, United States, 48109 收起 <<
NCT01076400	-		Terminated(The sponsor permane... 展开 >>ntly suspended new enrollment into the trial and discontinued the study; which was not related to any concerns over product safety.) 收起 <<	-	-
NCT01047007	Solid Tumors	Phase 1	Terminated(The study has been ... 展开 >>terminated due to business reasons.) 收起 <<	-	-
NCT01047007	-		Terminated(The study has been ... 展开 >>terminated due to business reasons.) 收起 <<	-	-
NCT01748825	Neoplasms Lym... 展开 >>phoma 收起 <<	Phase 1	Active, not recruiting	September 27, 2020	United States, Maryland ... 展开 >> National Institutes of Health Clinical Center, 9000 Rockville Pike Bethesda, Maryland, United States, 20892 收起 <<
NCT01164995	Epithelial Ovarian Cancer	Phase 2	Unknown	September 2013	Netherlands ... 展开 >> Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital Recruiting Amsterdam, Netherlands, 1066CX Contact: Jan HM Schellens, MD, PhD j.slijkerman@nki.nl Principal Investigator: Jan HM Schellens, MD, PhD 收起 <<

A549	200 nM	Apoptosis Assay	1 h	radiosensitizes NSCLC cells in a p53-dependent manner	21799033
ASPC-1		Growth Inhibition Assay		IC50=13.2 ± 1.1 μM	25458954
BxPC-3		Growth Inhibition Assay		IC50=0.8 ± 0.03 μM	25458954
Calu-6	200 nM	Apoptosis Assay	1 h	radiosensitizes NSCLC cells in a p53-dependent manner	21799033
CDC2		Growth Inhibition Assay		IC50＞1000 nM	23699655
CDK7		Growth Inhibition Assay		IC50＞1000 nM	23699655
CFPAC-1		Growth Inhibition Assay		IC50=3.3 ± 0.2 μM	25458954
CMK	10-10000 nM	Cell Viability Assay	72 h	reduces cell vialibity in a concentration-dependent manner	24962331
CMY	10-10000 nM	Cell Viability Assay	72 h	reduces cell vialibity in a concentration-dependent manner	24962331
Dayo		Growth Inhibition Assay		IC50=150 nM	24661910
H1299	200 nM	Apoptosis Assay	1 h	radiosensitizes NSCLC cells in a p53-dependent manner	21799033
H460	200 nM	Apoptosis Assay	1 h	radiosensitizes NSCLC cells in a p53-dependent manner	21799033
HL-60	125/250/500 nM	Growth Inhibition Assay	48 h	increases cell death in a concentration-dependent manner	25084614
HPAC		Growth Inhibition Assay		IC50=0.5 ± 0.01 μM	25458954
IST-MES1	150/250 nM	Cell Viability Assay	72 h	enhances the cisplatin cytotoxic effect in a concentration-dependent manner	24365782
IST-MES2	150/250 nM	Cell Viability Assay	72 h	enhances the cisplatin cytotoxic effect in a concentration-dependent manner	24365782
MIAPaCa-2		Growth Inhibition Assay		IC50=0.5 ± 0.05 μM	25458954
MOLM-13	125/250/500 nM	Growth Inhibition Assay	48 h	increases cell death in a concentration-dependent manner	25084614
MSTO-211H	150/250 nM	Cell Viability Assay	72 h	enhances the cisplatin cytotoxic effect in a concentration-dependent manner	24365782
MV4-11	125/250/500 nM	Growth Inhibition Assay	48 h	increases cell death in a concentration-dependent manner	25084614
MYT1		Growth Inhibition Assay		IC50=530 nM	23699655
NCI-H2052	150/250 nM	Cell Viability Assay	72 h	enhances the cisplatin cytotoxic effect in a concentration-dependent manner	24365782
NCI-H2452	150/250 nM	Cell Viability Assay	72 h	enhances the cisplatin cytotoxic effect in a concentration-dependent manner	24365782
OCI-AML3	125/250/500 nM	Growth Inhibition Assay	48 h	increases cell death in a concentration-dependent manner	25084614
PANC-1		Growth Inhibition Assay		IC50=10.6 ± 1.1 μM	25458954
REN	150/250 nM	Cell Viability Assay	72 h	enhances the cisplatin cytotoxic effect in a concentration-dependent manner	24365782
SK-N-AS		Growth Inhibition Assay		IC50=0.50 ± 0.02 μM	25308916
SK-N-AS	500 nM	Apoptosis Assay	48 h	induces cell apoptosis	25308916
SK-N-BE (2)		Growth Inhibition Assay		IC50=2.4 ± 0.3 μM	25308916
SK-N-BE (2), MK→PAN		Growth Inhibition Assay		IC50=2.4 ± 0.3 μM	25308916
SK-N-BE (2), PAN→MK		Growth Inhibition Assay		IC50=26.6 ± 9.6 μM	25308916
SK-N-DZ		Growth Inhibition Assay		IC50=0.36 ± 0.01 μM	25308916
SK-N-DZ	500 nM	Apoptosis Assay	48 h	induces cell apoptosis	25308916
T98G	100/250 nM	Apoptosis Assay	6 h	enhances radiation-induced cell killing	21992793
THP-1	125/250/500 nM	Growth Inhibition Assay	48 h	increases cell death in a concentration-dependent manner	25084614
U937	125/250/500 nM	Growth Inhibition Assay	48 h	increases cell death in a concentration-dependent manner	25084614
UW228		Growth Inhibition Assay		IC50=232 nM	24661910
WEE1		Growth Inhibition Assay		IC50=5.2 nM	23699655
WiDr	10-10000 nM	Kinase Assays	8 h	inhibits phosphorylation of CDC2 at Tyr15 with an EC50 value of 85 nmol/L pretreated with gemcitabine	19887545

MK-1775

MK-1775 纯度/质量文件产品仅供科研

全球学术期刊中引用的产品

MK-1775 质控信息

MK-1775 生物活性

MK-1775 细胞研究

MK-1775 临床研究

MK-1775 参考文献

MK-1775 实验方案

MK-1775 技术信息

最近浏览的产品

大规格询价

摩尔计算器

靶点

总药量计算器

工作液计算器

细胞研究

临床研究

确认信息

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

MK-1775

MK-1775 纯度/质量文件 产品仅供科研

全球学术期刊中引用的产品

MK-1775 质控信息

MK-1775 生物活性

MK-1775 细胞研究

MK-1775 临床研究

MK-1775 参考文献

MK-1775 实验方案

MK-1775 技术信息

最近浏览的产品

大规格询价

摩尔计算器

靶点

总药量计算器

工作液计算器

细胞研究

临床研究

确认信息

请登录您的专属账户

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

MK-1775 纯度/质量文件产品仅供科研